Atea Pharmaceuticals (AVIR) Cash from Investing Activities (2020 - 2026)
Atea Pharmaceuticals' Cash from Investing Activities history spans 6 years, with the latest figure at $29.7 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 65.26% to $29.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $132.9 million through Mar 2026, up 56.54% year-over-year, with the annual reading at $188.8 million for FY2025, 236.5% up from the prior year.
- Cash from Investing Activities came in at $29.7 million for Q1 2026, down from $46.6 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $124.7 million in Q2 2024 to a low of -$487.0 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is $27.8 million (2023), against an average of -$8.3 million.
- Year-over-year, Cash from Investing Activities skyrocketed 55736.36% in 2023 and then tumbled 112.13% in 2024.
- Atea Pharmaceuticals' Cash from Investing Activities stood at $33.5 million in 2022, then decreased by 17.07% to $27.8 million in 2023, then plummeted by 112.13% to -$3.4 million in 2024, then surged by 1482.55% to $46.6 million in 2025, then crashed by 36.17% to $29.7 million in 2026.
- Per Business Quant, the three most recent readings for AVIR's Cash from Investing Activities are $29.7 million (Q1 2026), $46.6 million (Q4 2025), and $41.3 million (Q3 2025).